Pharma Tech Focus April 2017

Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.

Japanese pharma company Takeda has announced it will buy Ariad Pharmaceuticals in a deal worth $5.2bn. The move is the latest in a tranche of deals involving Japanese companies setting their sights abroad, beyond their traditional domestic market. We take a look at the deal and find out what it can tell us about the wider market.

We also look into the US’s pharma manufacturing and drug supply chain after President Donald Trump emphasised a new focus on domestic production rather than outsourcing to plants in Asia, find out whether a treatment for Alzheimer’s could be used to regenerate decaying teeth, and explore the medicinal properties of turmeric.

Plus, we ask whether a map of all 1,578 drugs licensed through the FDA could point researchers to uncharted areas of research, and take a closer look at the importance of pharmacodynamics data in the wake of a disastrous clinical trial in France.

In this issue

Expanding Horizons
Japanese company Takeda has bought Ariad Pharmaceuticals for $5.2bn. Deals of this kind are becoming increasingly prevalent, as the Japanese pharma industry sets its sights beyond the traditional domestic market. Abi Millar reports.
Read the article.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Made in the USA
President Trump has indicated that he wants to reform US drug manufacturing, emphasising domestic production rather than outsourcing abroad. Abi Millar considers what it would take to shift the production base back inside US borders.
Read the article.

Unlocking Regenerative Medicine
Researchers at King’s College London have found a new use for an Alzheimer’s drug: repairing teeth. Elly Earls meets lead researcher Professor Paul Sharpe to find out more.
Read the article.

The Drugs Map
Innovation requires risks, but what if you could load the odds in your favour? Elly Earls meets cancer scientist Dr Bissan Al-Lazikani to find out how a new map of all existing drugs could help.
Read the article.

Turning to Turmeric
Turmeric has long been used as a natural remedy, and many studies seem to back that up. However, a recent review has suggested that many of the apparent benefits are bad science. Abi Millar finds out more.
Read the article.

Learning from Tragedy
The Rennes clinical trial disaster last year highlighted the dangers posed by first-in-human trials of high-risk drug candidates. Chris Lo finds out what makes early-stage trials go wrong.
Read the article.

Is Europe Ready?
Last month saw an important milestone for pharmaceutical manufacturers supplying the European market: the 9 February marked the beginning of the two-year countdown until the EU Falsified Medicines Directive comes into force. Christoph Krähenbühl, senior director at 3C Excellis Europe, reports.
Read the article.

Next issue preview

Last year ended with another disappointing result for Alzheimer’s treatments with the announcement that Eli Lilly’s solanezumab failed to slow progression in trials. While there has been no real breakthrough in recent years, the number of contenders has grown. We take a look at the most promising Alzheimer’s drugs in development.

We also explore whether the hormone kisspeptin could improve the safety of IVF for women, take a look at the true cost of failed drug development programmes, and find out more about a new mobile app called Cancergraph which is working to improve access to clinical trials in an attempt to benefit both patients and drug developers.

Plus, we zoom in on nanoparticles to find out how better access to the nanosphere could improve medicine, and speak to the Association for Packaging and Processing Technologies about
the key drivers for the pharmaceutical packaging sector moving forward.

Digital magazine FAQ

You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.

You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)